U.S. WorldMeds and Zambon Partner to Bring Newron Pharmaceuticals’ Parkinson’s Disease Treatment Xadago to the U.S.


(March 18, 2016) - Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, today announced a strategic agreement with US WorldMeds to commercialize Newron’s lead compound, Xadago® (safinamide), for the treatment of Parkinson’s disease in the U.S.  Read more…

Click for a printer friendly version

Back to top